Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510402 | 0.86 | CYP17A1 (0.67) | CYP17A1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL3360413 | 0.86 | CYP17A1 (0.63) | CYP17A1MAP4K4RXRARXRBP2RY14 | |
| SCHEMBL18570243 | 0.85 | CYP17A1 (0.61) | CYP17A1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL29435026 | 0.84 | HDAC3 (0.58) | CYP17A1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL222876 | 0.84 | HDAC3 (0.58) | CYP17A1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL12582106 | 0.84 | PTPN2 (0.48) | CYP17A1MEN1KMT2AMAP4K4RXRA | |
| SCHEMBL2344144 | 0.84 | NR1H4 (0.54) | CYP17A1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL7439456 | 0.83 | HDAC3 (0.57) | CYP17A1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL20865536 | 0.82 | CYP17A1 (0.68) | CYP17A1SMN1; SMN2MAP4K4 | |
| SCHEMBL21451461 | 0.82 | CYP17A1 (0.53) | CYP17A1KMT2AMAP4K4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665373-A2 | SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | SYMERES NETHERLANDS B.V. (NL) | 2025-05-08 | — | — | US | disclosed |
| CN-119301105-A | Thiostrepton-based compounds for the treatment of cancer and preparation thereof | RS肿瘤学有限责任公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2025-01-09 | — | — | US | disclosed |
| EP-4479390-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS Oncology, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024173644-A2 | SELECT THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2023158679-A2 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | RS ONCOLOGY, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011316-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | CYP17A1 609/4885MEN1 3826/4885NPC1 4062/4885 |
| US-20250144078-A1 | THIOSTREPTON-INSPIRED COMPOUNDS FOR TREATMENT OF CANCER AND PREPARATION THEREOF | TYMS, TOP1, TOP2A | CYP17A1 3920/4885MEN1 2742/4885NPC1 1571/4885 |
| US-20250381278-A1 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | PRDX1, PRDX2, PRDX6 | CYP17A1 499/4885MEN1 3803/4885NPC1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.